J&J’s FDA Bid Reignites the U.S. Robotics Surgery Battle

J&J’s OTTAVA filing raises the stakes as Intuitive and Medtronic vie for surgical dominance

19 Jan 2026

The contest to shape the next phase of robotic surgery in the United States is entering a more decisive stage. A regulatory filing submitted in early January signals that the market is shifting from limited adoption toward broader clinical use, raising the stakes for device makers and hospitals alike.

Johnson & Johnson has submitted its OTTAVA robotic surgery system to the Food and Drug Administration, seeking clearance through a pathway typically used for entirely new categories of medical devices. Regulatory filings are routine, but analysts said this one carries particular weight and reflects a strategic push to move robotic platforms beyond niche applications and into the center of general surgery. According to company statements, the goal is to support procedures performed at scale rather than in select specialties.

Those procedures include high-volume operations such as gastric bypass and hernia repair, which are carried out daily in hospitals across the country. For much of the past decade, robotic surgery has been most closely linked to urology and certain gynecological interventions. The next phase of growth is focused on common abdominal surgeries, where modest gains in efficiency or consistency can translate into meaningful systemwide effects.

Rival companies are positioning themselves for that shift. Medtronic received FDA clearance in 2023 for its Hugo robotic system in urologic surgery and has indicated plans to expand into general surgery, though broader indications remain under regulatory review. Intuitive Surgical, the long-established market leader, continues to benefit from its extensive installed base as it rolls out its latest da Vinci 5 system, reinforcing relationships with hospitals that have already invested heavily in robotic infrastructure.

The market is gradually evolving away from reliance on a single dominant platform toward a more competitive ecosystem that includes hardware, software, and service offerings. For hospitals, the promise of robotic surgery includes smaller incisions, faster recovery times, and more standardized outcomes, but it is balanced against substantial upfront costs, training requirements, and uncertainty about long-term regulatory pathways.

Industry observers said regulatory strategy is becoming nearly as important as technical performance. As approvals widen and adoption accelerates, robotic surgery is edging closer to routine care, a shift that could influence how operations are performed and which companies lead the field in the years ahead.